Gleevec/Glivec

Novartis pulls EMA application for expanded Tasigna use

molecular response' when treated with the company's Glivec/Gleevec (imatinib).

Niche-busting cancer immunotherapies

Novartis's Glivec represents the first real advance in getting 'under the hood' of cancer at the molecular level. ... By targeting a protein made by a mutated gene, Glivec has allowed chronic myeloid leukaemia (CML) patients to live nearly normal lives

Back to the future

Curiously, however, only five of the top 20 best-selling treatments are indicated for cancer: MabThera, Avastin, Herceptin, Glivec ($4.7b) and Revlimid ($4.3bn).

Pharma deals during April 2014

Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer);

Uptake challenges for personalised medicines and companion diagnostics

strategy (eg measuring peripheral blood BCR-ABL transcript levels in patients on Glivec to identify patients likely to achieve better long-term outcome if they are switched early to second-line

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]